The extensive pretrial proceedings mean the first Ozempic bellwether trials are unlikely to begin until at least 2026 or 2027.
Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Following the publication of recent studies, Danish health experts warn that they have received 19 reports of vision problems from Ozempic or Wegovy since July.
Findings are similar to those discovered by Harvard researchers in an Ozempic vision loss study published last summer.
With the first Ozempic lawsuit bellwether trials not expected to begin until at least late 2026 or early 2027, the court will address motions to dismiss and other “cross cutting” issues in 2025.
Lawsuit claims Novo Nordisk's failures to warn about the risk of gastroparesis and Ileus from Ozempic were "wanton, willful, fraudulent, reckless acts."
Tests found Ozempic caused the hearts of mice to atrophy, leaving researchers unsure whether the loss of cardiac muscle mass may occur in humans as well.
The Court may soon allow future lawsuits over Ozempic, Wegovy, Mounjaro and other GLP-1s to be brought using a Short Form Complaint, adopting allegations from the MDL Master Complaint.
Side effects of Wegovy caused a West Virginia woman to develop severe gastrointestinal problems, ileus and the need for her gallbladder to be surgically removed.
Amid increasing popularity of Ozempic, Wegovy and other GLP-1 drugs, researchers indicate that fewer patients are considering weight loss surgery.
